EISAI CO LTD

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock



Company Profile

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial figures, Fiscal year: from 01.04. to 31.03.

	202	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity	
Current assets	621,847,000,000		640,260,000,000		517,886,000,000		
Common stock capital		44,986,000,000		44,986,000,000		44,986,000,000	
Fixed assets	641,503,000,000		599,055,000,000		572,123,000,000		
Equity capital of a company		822,571,000,000		771,533,000,000		727,942,000,000	
Cash and cash equivalents	267,350,000,000		309,633,000,000		248,740,000,000		
Accrued liabilities		1,299,000,000		1,473,000,000		10,164,000,000	
Other assets	-		-		-		
Current liabilities		298,945,000,000		313,333,000,000		256,017,000,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		141,834,000,000		154,448,000,000		106,050,000,000	
Different income		-		-		-	
Other liabilities		19,096,000,000		19,407,000,000		4,092,000,000	
Total assets	1,263,350,000,000	1,263,350,000,000	1,239,315,000,000	1,239,315,000,000	1,090,009,000,000	1,090,009,000,000	

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	11,076	11,322	11,237
Equity ratio	66.90%	64.09%	69.05%
Debt-equity ratio	49.48%	56.04%	44.81%

Others

	2023	2022	2021
Tax Expense Rate	-26.27%	16.05%	19.16%

EISAI CO LTD

ISIN: JP3160400002 WKN: 4523 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	744,402,000,000	756,226,000,000	645,942,000,000
Net income	55,432,000,000	47,954,000,000	42,119,000,000
EBIT	255,930,000	326,802,000	314,658,000
Operating income before taxes	45,012,000,000	54,458,000,000	52,551,000,000
Cash Flow	-1,772,000,000	117,590,000,000	73,853,000,000
Net interest income	2,357,000,000	-9,000,000	108,000,000
Research and development expenses	156,691,000,000	158,030,000,000	138,822,000,000
Income taxes	-11,824,000,000	8,741,000,000	10,068,000,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	403,251	400,756	344,901

Board of Directors		
Clive Thornley	Member of Supervisory Board	
Fumihiko Ike	Member of Supervisory Board	
Hideki Hayashi	Member of Supervisory Board	
Hideyo Uchiyama	Member of Supervisory Board	
Hiroyuki Kato	Member of Supervisory Board	
Ryota Miura	Member of Supervisory Board	
Toru Moriyama	Member of Supervisory Board	
Yoshiteru Kato	Member of Supervisory Board	
Yuko Yasuda	Member of Supervisory Board	
Yumiko Miwa	Member of Supervisory Board	

Members of Management Board			
Haruo Naito	Chairman of Managing Board		
Akiko Nakahama	Member of Executive Committee		
Gary Hendler	Member of Executive Committee		
Ivan Cheung	Member of Executive Committee		
Kazuhiko Tamura	Member of Executive Committee		
Keisuke Naito	Member of Executive Committee		
Kenta Takahashi	Member of Executive Committee		
Lynn Kramer	Member of Executive Committee		
Masatomi Akana	Member of Executive Committee		
Mitsuo Kosaka	Member of Executive Committee		
Mitsuru Shomon	Member of Executive Committee		
Sayoko Sasaki	Member of Executive Committee		
Shin Ujiie	Member of Executive Committee		
Shohei Kanazawa	Member of Executive Committee		
Takashi Owa	Member of Executive Committee		
Tatsuyuki Yasuno	Member of Executive Committee		
Terushige like	Member of Executive Committee		
Teruyuki Masaka	Member of Executive Committee		
Toshitaka Asano	Member of Executive Committee		
Yanhui Feng	Member of Executive Committee		
Yasushi Okada	Member of Executive Committee		